Iconic Therapeutics

Treatments for retinal disease and cancer

Iconic Therapeutics is a clinical-stage biopharmaceutical company dedicated to translating scientific insight into breakthrough medicines. Iconic has a deep understanding of the role of tissue factor (TF) in angiogenesis, inflammation, and metastasis which has led it to develop a new approach to retinal disease and cancer. Their lead product candidate, ICON-1, is a novel immune-conjugate fusion protein. ICON-1 works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of leading causes of blindness.